Gilead Acquires Tubulis for $3.15 Billion to Enhance Pipeline
Gilead Sciences announced on Tuesday the acquisition of Tubulis, a Munich-based startup, for a $3.15 billion upfront cash payment, with potential additional payments of up to $1.85 billion tied to milestone achievements, as part of its strategy to build out its drug pipeline. According to Dealbreaker, this deal marks Gilead’s third M&A announcement this year and includes Tubulis’s two targeted therapies in clinical testing for cancer, along with platform technologies that could apply to other therapeutic areas.
The Acquisition Details
The agreement involves Gilead paying $3.15 billion upfront, according to financial terms announced Tuesday, and acquiring Tubulis’s antibody drug conjugates (ADCs) that aim to improve targeted cancer therapies. Tubulis specializes in ADCs, which link antibodies to toxic payloads, and its technologies produce more stable ADCs to reduce off-target toxicity, as noted in a 2024 interview with CEO Dominik Schumacher. These technologies stem from research at the Leibniz Research Institute in Berlin and the Ludwig Maximilians University in Munich, and they enable the development of ADCs with more potent payloads.
Tubulis’s Pipeline and Technologies
Tubulis’s lead program, TUB-040, targets the NaPi2b protein and is in Phase 1b/2 testing for platinum-resistant ovarian cancer and non-small cell lung cancer, with interim data from last fall’s European Society for Medical Oncology meeting showing a 50% overall response rate in 66 evaluable patients and generally well-tolerated side effects, mostly Grade 1 or 2. Following this data presentation, Tubulis closed its Series C financing round at €344 million (about $401 million), adding new investors. The company’s next program, TUB-030, targets the 5T4 protein and is being assessed in a basket study for 13 types of solid tumors.
Gilead’s Strategic Moves
Gilead and Tubulis had established a partnership in 2024, where Gilead paid $20 million upfront to collaborate on an ADC for an undisclosed target, granting Gilead an exclusive option to license the program, according to Dealbreaker. Gilead CEO Daniel O’Day stated that this collaboration confirmed the value of Tubulis’s programs and research capabilities, which could expand Gilead’s pipeline in oncology, immunology, and virology. Earlier this year, Gilead completed deals to acquire Arcellx for $7.8 billion in February and Ouro Medicines for about $1.7 billion in March, both including platform technologies for drug development. As widely known in the biotech sector, Gilead has historically focused on virology but is increasingly prioritizing oncology and immunology for growth.
Analyst Perspectives
Leerink Partners analyst Daina Graybosch highlighted in her research note that Tubulis’s platforms could drive future pipeline innovation at Gilead by integrating with its medicinal chemistry capabilities, potentially leading to new ADC payloads for oncology, inflammation, and virology. According to Dealbreaker, Gilead’s communications suggested similarities to Merck’s $9.2 billion acquisition of Cidara, where platform technologies extended beyond the lead program into other areas like cancer treatments.
